Rethinking ‘top‐down’ and ‘bottom‐up’ roles of top and middle managers in organizational change: implications for employee support

In this study we integrate insights from ‘top‐down’ and ‘bottom‐up’ traditions in organizational change research to understand employees’ varying dispositions to support change. We distinguish between change initiation and change execution roles and identify four possible role configurations in which top managers (TMs) and middle managers (MMs) can feature in change. We contend that both TMs and MMs can play change initiation and/or change execution roles, TMs and MMs have different strengths and limitations for taking on different change roles, and their relative strengths and limitations are compounded or attenuated based on the specific configuration of change roles. We subsequently hypothesize employee support for change in relation to different TM‐MM change role configurations. Our findings show that change initiated by TMs does not engender above‐average level of employee support. However, change initiated by MMs engenders above‐average level of employee support, and even more so, if TMs handle the change execution

Neutron-capture gamma-ray study of levels in Ba135 and description of nuclear levels in the interacting-boson-fermion model

We have performed neutron-capture gamma-ray studies on natural and enriched targets of 134Ba in order to investigate the nuclear levels of 135Ba. The low-energy level spectra were compared with the calculations using the interacting-boson-fermion model (IBFM) and the cluster-vibration model. The level densities up to 5 MeV that are calculated within the IBFM are in accordance with the constant temperature Fermi gas model. From the spin distribution we have determined the corresponding spin cutoff parameter σ and compared it to the prediction from nuclear systematics

Evaluation of simulated CO₂ power plant plumes from six high-resolution atmospheric transport models

Global anthropogenic CO2 sources are dominated by power plants and large industrial facilities. Quantifying the emissions of these point sources is therefore one of the main goals of the planned constellation of anthropogenic CO2 monitoring satellites (CO2M) of the European Copernicus program. Atmospheric transport models may be used to study the capabilities of such satellites through observing system simulation experiments and to quantify emissions in an inverse modelling framework. How realistically the CO2 plumes of power plants can be simulated and how strongly the results may depend on model type and resolution, however, is not well known due to a lack of observations available for benchmarking. Here, we use the unique data set of aircraft in-situ and remote sensing observations collected during the CoMet measurement campaign down-wind of the coal fired power plants at Bełchatów in Poland and Jaenschwalde in Germany in 2018 to evaluate the simulations of six different atmospheric transport models

International Paediatric Mitochondrial Disease Scale

published_or_final_versio

Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease

Leigh Disease is a progressive neurometabolic disorder for which a clinical effective treatment is currently still lacking. Here, we report on the therapeutic efficacy of KH176, a new chemical entity derivative of Trolox, in Ndufs4 (-/-) mice, a mammalian model for Leigh Disease. Using in vivo brain diffusion tensor imaging, we show a loss of brain microstructural coherence in Ndufs4 (-/-) mice in the cerebral cortex, external capsule and cerebral peduncle. These findings are in line with the white matter diffusivity changes described in mitochondrial disease patients. Long-term KH176 treatment retained brain microstructural coherence in the external capsule in Ndufs4 (-/-) mice and normalized the increased lipid peroxidation in this area and the cerebral cortex. Furthermore, KH176 treatment was able to significantly improve rotarod and gait performance and reduced the degeneration of retinal ganglion cells in Ndufs4 (-/-) mice. These in vivo findings show that further development of KH176 as a potential treatment for mitochondrial disorders is worthwhile to pursue. Clinical trial studies to explore the potency, safety and efficacy of KH176 are ongoing

Embedded Fixers, Pragmatic Experimenters, Dedicated Activists: Evaluating Third-Party Labour Market Actors’ Initiatives for Skilled Project-Based Workers in the Gig Economy

Non-standard career paths — in which workers jump from one employment arrangement to another according to the projects they work on — have become more frequent in modern labour markets. The traditional solutions for organizing and managing work relationships and job transitions have become less effective for such workers regarding the risks of precariousness and economic dependence they may experience. Envisioning ways forward requires an appreciation of what was achieved over the past century and an understanding of what is needed to replace and adapt these achievements. Emerging solutions for managing work relationships are provided by a growing range of third-party labour market actors, but the evaluation of their contributions in the literature remains limited. In this article, we build an original theoretical framework to evaluate such contributions according to the kind of services they provide and their respective engagement in institutional innovation. We give examples of solutions developed for skilled workers in two institutional contexts: the Netherlands and Belgium and show how our framework can help distinguish at least three groups of actors that contribute to labour market development in different ways

Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma

Background: The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors. Methods: Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012. Observed SMN numbers were compared with expected cancer incidence to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10 000 person-years). Treatment-specific risks were assessed using multivariable Cox regression. Results: After a median follow-up of 13.8 years, 321 survivors developed one or more SMNs (SIR 1.5, 95% CI 1.3-1.8, AER 51.8). SIRs remained increased for at least 20 years after first-line treatment (SIR ≥20-year follow-up 1.5, 95% CI 1.0-2.2, AER 81.8) and were highest among patients ≤40 years at first DLBCL treatment (SIR 2.7, 95% CI 2.0-3.5). Lung (SIR 2.0, 95% CI 1.5-2.7, AER 13.4) and gastrointestinal cancers (SIR 1.5, 95% CI 1.2-2.0, AER 11.8) accounted for the largest excess risks. Treatment with &gt;4500 mg/m2 cyclophosphamide/&gt;300 mg/m2 doxorubicin versus ≤2250 mg/m2/≤150 mg/m2, respectively, was associated with increased solid SMN risk (hazard ratio 1.5, 95% CI 1.0-2.2). Survivors who received rituximab had a lower risk of subdiaphragmatic solid SMNs (hazard ratio 0.5, 95% CI 0.3-1.0) compared with survivors who did not receive rituximab. Conclusion: Five-year DLBCL survivors have an increased risk of SMNs. Risks were higher for survivors ≤40 years at first treatment and survivors treated with &gt;4500 mg/m2 cyclophosphamide/&gt;300 mg/m2 doxorubicin, and may be lower for survivors treated in the rituximab era, emphasizing the need for studies with longer follow-up for rituximab-treated patients.</p